drugset / Trial / NCT06300203

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

NCT06300203

Phase 2 Recruiting 120 enrolled Beijing Tongren Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Timeline

Start
2024-03-18
Primary completion
2026-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CM310 Monoclonal antibody Subcutaneous